The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. - Wikidata - awgldk - TriplyDB

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

http://www.wikidata.org/entity/Q36242802

about

Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy Mirk/dyrk1B kinase is upregulated following inhibition of mTOR.REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancer Green tea polyphenols induce p53-dependent and p53-independent apoptosis in prostate cancer cells through two distinct mechanisms First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.New developments in the treatment of ovarian cancer--future perspectives.Ascites analysis by a microfluidic chip allows tumor-cell profiling.Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.Cancer-specific interruption of glucose metabolism by resveratrol is mediated through inhibition of Akt/GLUT1 axis in ovarian cancer cells.Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer.LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway.A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.Silencing of type Iγ phosphatidylinositol phosphate kinase suppresses ovarian cancer cell proliferation, migration and invasion.Utilizing the Luminex Magnetic Bead-Based Suspension Array for Rapid Multiplexed Phosphoprotein Quantification.Akt activation by Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells.Increased Expression of Phosphatidylinositol 3-Kinase p110α and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies

P2860

Q28383349-EE22B275-26C8-4A7E-9F5D-71BF1156F4F2 Q30881669-9D593A01-4068-4BC4-B388-6CDAAE53B272 Q34068827-BC42C34A-B147-475A-8FF4-752AFA5F007E Q34096774-E9348F49-9CE5-41DD-8093-DC2FFB07CD79 Q34371477-DE22B131-8550-4A2E-854A-9FA0ED712152 Q34534169-28D8B1B7-A12E-4840-A82D-A329CC72ED28 Q34626967-E55496DB-9EBD-44C4-961F-486BD17B1AAF Q35133375-E3D2074D-46A4-4737-96D7-A7D3DBCA9131 Q36358324-539A1951-3F52-4613-868D-E1814A972CC3 Q36413165-0299F084-1561-45A9-B6CA-64C09F02BDBC Q36820568-A836BA13-8E46-45B7-93E8-71CE4B89BFD0 Q37022406-632C3CF4-A845-4890-B5F3-55AD2756945D Q37196532-631D67FA-7FDD-4148-A9C4-A2BDA9ECBA52 Q37225222-434D5B7F-F097-4D82-A234-75FFCEC1E913 Q37332487-69C53C33-AF2E-4716-9F23-814ADB035D87 Q37409535-396FD1DA-701D-4225-BC30-74EA095732DE Q37420213-B5561207-180C-40CC-AB27-3364EF0E946E Q38757645-CF459EA2-4ABB-4B38-A152-60346999EACD Q38948714-4F5EF140-DF7F-4BD2-B51C-41027C7D3C5F Q38988072-7D7E28D0-AA66-4477-BF47-38C352672C65 Q42266429-950B9655-9C40-4ACE-929C-B3BF738A18CC Q42370827-94AF6624-4402-4345-87A7-5FA6E25DBACC Q45334548-63B83911-8680-4782-8F02-50BD852A4193 Q48124146-5C08D09A-FD2D-4DD1-8355-9182326BF80E Q49393542-882FF41C-D67F-4457-BDD8-7A5B4F79BE85 Q49478004-1F8E1ED0-B84C-4C2B-84AE-43D7E136DE33 Q49887901-B51650D7-83BA-4724-92C7-8FFA33AECC03 Q50611919-231B4198-83F3-43F5-9FAA-AF05B6663CFB Q50878626-AE80AA69-F3F2-4157-87F7-00A8F5FCC096 Q50932992-44318330-BEB9-4283-B268-6AAAE9715436 Q55036376-14D2A952-5E8A-4800-BAD3-BBA60D1DF007 Q58775646-BF186C6A-46A2-4544-A8FE-8E0BB5CF5F6B Q58790039-B791D803-9575-49A5-8B85-A6155AE4CD3D

P2860

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

http://www.wikidata.org/entity/Q36242802

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

@ast

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

@en

type

label

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

@ast

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

@en

prefLabel

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

@ast

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

@en

P1433

Q36242802-CBC7DC42-28AA-4591-AEA0-78207661CE70

P1476

Q36242802-1EA47A19-B57B-435C-A938-66279F45F223

P2093

Q36242802-128BC740-CD48-4B6C-9159-B611E97D4FEF

Q36242802-1733BD92-E22C-4CCD-BBB9-D00B325AD673

Q36242802-20F4897C-4E9C-4CF2-BED3-3D3315D80668

Q36242802-23809B1F-7776-4DDA-AB7F-5DF80771A11F

Q36242802-460247E2-954B-45B3-8E07-4AF35BB61FEF

Q36242802-5F502160-2B5D-4E9B-869A-792104A737A6

Q36242802-669121B1-BA0A-4B08-97D5-B860069313EA

Q36242802-C880E162-13B8-470D-913C-E2B3705C9C9E

Q36242802-DB967D97-A4E2-4B92-8473-727E88D2FF45

Q36242802-EA56C532-0DF3-48BF-81C9-548BAD3B4A5C

P2860

Q36242802-01D53A13-52E0-4DD9-B0E9-B7CF5418BA82

Q36242802-05D6A6E4-21D4-49EE-AA26-335CDAFE45AF

Q36242802-0764BD36-5E0C-4F00-B6BA-99CE88122D8B

Q36242802-0AA75895-BDFE-4793-9173-B3B66BCAF7F2

Q36242802-2A4A0A0B-E168-450B-A3F3-FCAE9D64B06C

Q36242802-2D4EF9DD-198A-40C9-97A9-38B9E12C595F

Q36242802-2E6BE259-7030-43D6-BB85-AF0254E6CACA

Q36242802-3244C6DC-C726-4F7B-B3D5-CE1BBF9E4792

Q36242802-335DFF03-0BCA-483F-B3EB-EEAB19F91556

Q36242802-3A678CBD-4C69-44FE-BEBE-AF113950B877

P304

Q36242802-3B28DDEC-EACC-47DF-BA8A-D93E69B259CF

P31

Q36242802-D4F57E62-443B-481A-B5E4-929A8409E537

P356

Q36242802-18AD78C1-185F-4F5A-8226-7F138A0A7157

P433

Q36242802-488FA7A0-9300-49F4-B908-9A9594316434

P478

Q36242802-559BF85D-64CB-4684-9ECC-D2B8CF834822

P50

Q36242802-06BC4397-ED83-494F-B0E8-4F5D89E7E5A3

Q36242802-1EECB13F-5771-4C9B-BBF0-239EA634FEB8

Q36242802-79E26203-E7DB-4AC6-8E1A-B27FDB00CF02

Q36242802-9FD7FB5F-0111-4132-828D-7728E05AC2F7

Q36242802-FDC8240B-61C1-407B-9868-FE010C362EA0

P577

Q36242802-D1EF7AF4-F731-421D-ADD3-987D329169EC

P698

Q36242802-5236C381-4D99-4813-B25F-F6509669CFF0

P921

Q36242802-F30B9ECC-A206-4943-873F-210448B65D66

P932

Q36242802-4A7D1454-D907-4B87-8363-CB4441D80F8A

P356

1535-7163.MCT-11-0996

P1433

Molecular Cancer Therapeutics

P1476

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer

@en

P2093

Adam Stewart

http://www.w3.org/2001/XMLSchema#string

Craig P Carden

http://www.w3.org/2001/XMLSchema#string

Emma Kipps

http://www.w3.org/2001/XMLSchema#string

Johann S de Bono

http://www.w3.org/2001/XMLSchema#string

Lorna Pope

http://www.w3.org/2001/XMLSchema#string

Martin Gore

http://www.w3.org/2001/XMLSchema#string

Michelle D Garrett

http://www.w3.org/2001/XMLSchema#string

Parames Thavasu

http://www.w3.org/2001/XMLSchema#string

Paul Workman

http://www.w3.org/2001/XMLSchema#string

Stan B Kaye

http://www.w3.org/2001/XMLSchema#string

P2860

URI is an oncogene amplified in ovarian cancer cells and is required for their survival

Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K

Isolation of rare circulating tumour cells in cancer patients by microchip technology

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer.

P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression

Global cancer statistics in the year 2000.

P304

1609-1617

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-11-0996

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Gerhardt Attard

P577

2012-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22556379

http://www.w3.org/2001/XMLSchema#string

P921

P932

4630857

http://www.w3.org/2001/XMLSchema#string